- Helomics
chief technology officer speaks at inaugural UK 100,000 Genomes Project
Conference
- The
100,000 Genomes Project is a UK-government project, sequenced whole
genomes from National Health Service patients
- The
depth of the project data is best in class, yielding useful benchmarks to
help validate Helomics models
Dr. Mark Collins, chief technology officer of Predictive
Oncology Inc.’s (NASDAQ: POAI) Helomics subsidiary, recently spoke at
the inaugural UK 100,000 Genomes Project Conference. Collins presented initial
findings from Helomics’ analysis of UK 100,000 Genomes Project (“UK100K GP”)
data toward Helomics’ goal of building AI-driven predictive models of ovarian
cancer. The inaugural conference was hosted by Genomics England on November 4
in London.
According to Global Market Insights Inc., the precision
medicine market is forecast to reach more than $96 billion by 2024. Helomics is
an innovative precision-medicine company positioned for growth in this growing
market. A subsidiary of Predictive Oncology, Helomics is dedicated to
improving the standard of care for cancer patients by harnessing the power of a
patient’s own living tumor to build multi-omics AI-driven predictive models of
tumor drug response to improve clinical outcomes for patients.
The 100,000 Genomes Project is a United Kingdom government
endeavor that is sequencing whole genomes from National Health Service
patients (http://ibn.fm/M9bGx).
The project focuses on rare diseases, some common types of cancer and
infectious diseases. Recruitment of participants to the 100,000 Genomes Project
was completed in 2018, with the 100,000th sequence achieved in December 2018.
The aim of the project is to transform health care through new diagnoses and
personalized treatments.
Helomics partnered with the UK100K GP last year to bring its
invaluable expertise and data to the groundbreaking research. The company is
leveraging its proprietary, multi-omic database of tumor-drug-response profiles
using the proven power of AI to build predictive models of ovarian cancer. The
goal is for these AI-driven predictive models to be used by clinicians to
individualize treatment options and by pharma researchers to develop new
targeted therapies in the quest to improve outcomes for women with ovarian
cancer.
“This partnership is key to our approach of building
AI-driven predictive models,” said Collins. “We are delighted to participate in
the scientific session, panel discussion and an invite-only session on the
expansion of the UK 100,000 Genomes Project to 5 million genomes. The depth of
both the genomic and clinical data for ovarian cancer from the project is best
in class, yielding useful benchmarks to validate our models. Over the next
year, we intend to explore additional projects to enable use of our AI-driven
predictive models to improve outcomes for ovarian cancer patients in the UK, as
well as seek partnerships with UK pharma companies for the development of new
precision ovarian cancer therapies.”
In addition to speaking during the scientific session of the
conference, Collins also participated in an invitation-only session focused on
the expansion of the UK 100K GP to 5 million genomes.
Based in Eagan, Minnesota, Predictive Oncology operates
through three business units: Helomics, TumorGenesis and Skyline Medical.
Predictive Oncology works together with the pharmaceutical, diagnostic and
biotechnology industries to develop highly customizable assessment methods that
can lead to more effective treatments for patients. Predictive Oncology
continues to take advantage of the synergies of its subsidiaries to bring
precision medicine to the treatment of cancer. The company is at the vanguard
of innovation in using AI in improving outcomes for cancer patients. For
investors, Predictive Oncology offers the potential for significant ROI as it
focuses on improving patient outcomes.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
